1. Home
  2. NTRA vs CHRW Comparison

NTRA vs CHRW Comparison

Compare NTRA & CHRW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NTRA
  • CHRW
  • Stock Information
  • Founded
  • NTRA 2003
  • CHRW 1905
  • Country
  • NTRA United States
  • CHRW United States
  • Employees
  • NTRA N/A
  • CHRW N/A
  • Industry
  • NTRA Medical Specialities
  • CHRW Oil Refining/Marketing
  • Sector
  • NTRA Health Care
  • CHRW Consumer Discretionary
  • Exchange
  • NTRA Nasdaq
  • CHRW Nasdaq
  • Market Cap
  • NTRA 13.7B
  • CHRW 12.1B
  • IPO Year
  • NTRA 2015
  • CHRW 1997
  • Fundamental
  • Price
  • NTRA $129.95
  • CHRW $99.66
  • Analyst Decision
  • NTRA Strong Buy
  • CHRW Hold
  • Analyst Count
  • NTRA 15
  • CHRW 16
  • Target Price
  • NTRA $123.64
  • CHRW $92.64
  • AVG Volume (30 Days)
  • NTRA 1.2M
  • CHRW 961.5K
  • Earning Date
  • NTRA 11-06-2024
  • CHRW 10-30-2024
  • Dividend Yield
  • NTRA N/A
  • CHRW 2.48%
  • EPS Growth
  • NTRA N/A
  • CHRW N/A
  • EPS
  • NTRA N/A
  • CHRW 2.78
  • Revenue
  • NTRA $1,360,503,000.00
  • CHRW $17,458,576,000.00
  • Revenue This Year
  • NTRA $42.99
  • CHRW $4.07
  • Revenue Next Year
  • NTRA $13.11
  • CHRW $3.71
  • P/E Ratio
  • NTRA N/A
  • CHRW $36.00
  • Revenue Growth
  • NTRA 46.13
  • CHRW N/A
  • 52 Week Low
  • NTRA $36.90
  • CHRW $65.00
  • 52 Week High
  • NTRA $128.28
  • CHRW $105.41
  • Technical
  • Relative Strength Index (RSI)
  • NTRA 66.43
  • CHRW 49.29
  • Support Level
  • NTRA $114.62
  • CHRW $97.77
  • Resistance Level
  • NTRA $118.52
  • CHRW $102.56
  • Average True Range (ATR)
  • NTRA 4.62
  • CHRW 1.80
  • MACD
  • NTRA 0.87
  • CHRW -0.77
  • Stochastic Oscillator
  • NTRA 99.77
  • CHRW 26.60

About NTRA Natera Inc.

Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.

About CHRW C.H. Robinson Worldwide Inc.

C.H. Robinson is a top-tier non-asset-based third-party logistics provider with a significant focus on domestic freight brokerage (about 61% of net revenue), which reflects mostly truck brokerage but also rail intermodal. Additionally, the firm operates a large air and ocean forwarding division (27%), which has grown organically and via tuck-in acquisitions over the years. The remainder of revenue consists of the European truck-brokerage division, transportation management services, and a legacy produce-sourcing operation.

Share on Social Networks: